Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
How to use artificial intelligence to strengthen scientific processes and scholarly output
As AI-driven systems are integrated into all aspects of science, we need to make sure that they read and write to a shared data and knowledge space.
How to use artificial intelligence to strengthen scientific processes and scholarly output
As AI-driven systems are integrated into all aspects of science, we need to make sure that they read and write to a shared data and knowledge space.
The fast-expanding repertoire of mitochondria in the brain
More than cellular powerhouses, these organelles also seem to help synapses communicate, support memory formation and even shape behavior.
The fast-expanding repertoire of mitochondria in the brain
More than cellular powerhouses, these organelles also seem to help synapses communicate, support memory formation and even shape behavior.
When autistic kids grow up, Chapter 5: The war dial
“You have to reshape the whole system.” Tempest McDonald earns a measure of peace.
When autistic kids grow up, Chapter 5: The war dial
“You have to reshape the whole system.” Tempest McDonald earns a measure of peace.